期刊
FUTURE MEDICINAL CHEMISTRY
卷 11, 期 2, 页码 119-135出版社
FUTURE SCI LTD
DOI: 10.4155/fmc-2018-0248
关键词
cancer; chemoresistance; chemotherapy; cisplatin; metal-based anticancer agents
资金
- Avner Pancreatic Cancer Foundation
- Keith & Ann Vaughan Fund
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据